Insmed Incorporated (INSM) Stock

Insmed Incorporated (INSM) is a Healthcare stock trading at $95.78 (as of 2026-06-18), with a market capitalization of $23.17B and a trailing P/E of -18.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for serious and rare diseases. Its marketed treatment ARIKAYCE is used with other antibacterial therapy for adult patients with Mycobacterium avium complex lung disease, and it also develops brensocatib and inhaled treprostinil palmitil for specific rare lung indications.

Valuation — source: SEC EDGAR (first-party)
Price	$95.78
Market Cap	$23.17B
P/E Ratio	-18.6
EV / EBITDA	-20.3
Price / Book	32.88
Price / Sales	28.27
DCF Value (model)	$-76.56
DCF Upside vs Price	-179.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$606.42M
Net Margin	-210.5%
Return on Equity	-167.9%
Debt / Equity	0.77
Current Ratio	4.47
Revenue Growth (YoY)	229.6%
EPS Growth (YoY)	-46.5%
FCF Growth (YoY)	-16.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	3.79 (safe)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-18.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-188.6%
vs Industry	-207.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JPMORGAN CHASE & CO ($3.70B)
Institutional Holders Tracked	10
Congressional Trades (recent)	9

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	William H. Lewis
Employees	1,271
Country	US
IPO Date	2000-06-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.